Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-05402536
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
PF-05402536 is an investigational therapeutic vaccine developed for smoking cessation. It functions as an immunostimulant, aiming to generate an immune response against nicotine to reduce its psychoactive effects, thereby assisting smokers in quitting. The drug is classified as both a therapeutic and toxoid vaccine, targeting the nicotine molecule itself rather than a biological receptor or protein. The developer and sponsor of clinical trials is Pfizer. PF-05402536 has undergone phase 1 clinical testing for safety, tolerability, immunogenicity, and exploratory efficacy in adult smokers motivated to quit[1][3][9].
- Other names
- NIC7-001NIC-7-001NIC 7-001
Beyond the preview
Go deeper on PF-05402536.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-05402536.